Intersect ENT Inc (XENT) Stock Is An 52-Week High Flier

July 17, 2017 - By Peter Erickson

The stock of Intersect ENT Inc (NASDAQ:XENT) hit a new 52-week high and has $30.48 target or 6.00 % above today’s $28.75 share price. The 8 months bullish chart indicates low risk for the $853.71M company. The 1-year high was reported on Jul, 17 by If the $30.48 price target is reached, the company will be worth $51.22M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 184,115 shares traded. Intersect ENT Inc (NASDAQ:XENT) has risen 79.98% since July 17, 2016 and is uptrending. It has outperformed by 63.28% the S&P500.

Wall Street await Intersect ENT Inc (NASDAQ:XENT) to release earnings on August, 1. Analysts forecast EPS of $-0.21, exactly $0.00 or 0.00 % from 2014’s $-0.21 EPS. After posting $-0.23 EPS for the previous quarter, Intersect ENT Inc’s analysts now forecast -8.70 % EPS growth.

Intersect ENT Inc (NASDAQ:XENT) Ratings Coverage

Among 8 analysts covering Intersect ENT (NASDAQ:XENT), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Intersect ENT had 10 analyst reports since August 17, 2015 according to SRatingsIntel. JP Morgan downgraded the shares of XENT in report on Wednesday, November 2 to “Neutral” rating. Canaccord Genuity maintained Intersect ENT Inc (NASDAQ:XENT) rating on Monday, August 17. Canaccord Genuity has “Buy” rating and $32 target. The stock of Intersect ENT Inc (NASDAQ:XENT) earned “Overweight” rating by Piper Jaffray on Tuesday, September 29. Northland Capital initiated Intersect ENT Inc (NASDAQ:XENT) on Tuesday, March 29 with “Outperform” rating. Northland Capital downgraded the stock to “Market Perform” rating in Wednesday, May 31 report. The firm has “Hold” rating given on Thursday, October 6 by Deutsche Bank. The rating was initiated by Bank of America on Friday, December 18 with “Buy”. On Thursday, October 1 the stock rating was maintained by Canaccord Genuity with “Buy”.

More notable recent Intersect ENT Inc (NASDAQ:XENT) news were published by: which released: “Why Intersect ENT Shares Are Crashing 43% Today” on November 02, 2016, also with their article: “Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL” published on February 24, 2017, published: “Intersect ENT Reports First Quarter 2017 Results” on May 02, 2017. More interesting news about Intersect ENT Inc (NASDAQ:XENT) were released by: and their article: “Intersect ENT Announces PDUFA Date for Office-Based SINUVAâ„¢ Steroid Releasing …” published on May 22, 2017 as well as‘s news article titled: “Intersect ENT to Report Second Quarter 2017 Financial Results” with publication date: July 14, 2017.

Intersect ENT, Inc. is a commercial-stage drug-device company. The company has market cap of $853.71 million. The Firm develops drugs for patients with ear, nose and throat conditions. It currently has negative earnings. The Firm has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.